“We believe that its potential for enhancing therapeutics for different diseases is practically endless.”
Researchers at Tel Aviv University, led by Prof. Ronit Satchi-Fainaro of TAU’s Department of Physiology and Pharmacology at the Sackler School of Medicine, have developed an innovative nanotechnological drug delivery system that significantly enhances the effectiveness of treatment for the aggressive skin cancer melanoma.
The nanocarrier is a biocompatible and biodegradable polymer, which comprises repeating units of glutamic acids. It packages together two drugs belonging to different families with proven efficacy for the treatment of melanoma: BRAF inhibitors (Dabrafenib) and MEK inhibitors (Selumetinib, approved for use in children with neurofibromatosis type I).
The research group included PhD students Evgeni Pisarevsky, Dr. Rachel Blau, and Yana Epshtein from Prof. Satchi-Fainaro’s research laboratory at the Sackler School. The paper was published on August 10, 2020, in Advanced Therapeutics.
“One of the major obstacles of the biological treatments is that, after a while, the cancer cells develop resistance to the drugs,” Prof. Satchi-Fainaro says. “We assume that by precise delivery of two or more targeted drugs that will attack the cancer cells forcefully and simultaneously from different directions, we can delay or even prevent the acquisition of this drug resistance.
“In this project, we looked for a solution to a problem often associated with drug cocktails,” Prof. Satchi-Fainaro continues. “Most oncological treatments today are administered in the form of cocktails of several medications. But even though the drugs are administered simultaneously, they do not reach the tumor at the same time, due to differences in basic parameters, like how long they survive in the bloodstream and the time it takes each drug to reach the tumor tissue. Thus, in most cases, the medications do not work concurrently, which prevents them from attaining optimal synergistic activity.”
Responding to these challenges, the researchers developed an innovative, efficient, and biodegradable drug delivery system. Two drugs known to be effective for the treatment of melanoma, Dabrafenib and Selumetinib, were chosen, with the intention of delivering them jointly to the tumor using a nanocarrier. The drug nanocarrier chosen for the task was PGA, a polymer of glutamic acid, one of nature’s most common amino acids. Developed in Prof. Satchi-Fainaro’s lab several years ago, the nanocarrier has already been tested successfully for treating pancreatic, breast, and ovarian cancer in animal models.
The researchers first determined the optimal ratio between the two medications based on levels and types of toxicity, as well as the resistance mechanism developed by cancer cells for each medication. This would ultimately ensure maximum effectiveness, minimal toxicity, and optimal synergistic activity. Another important advantage of joint delivery is reduced dosage: a much lower dose is required compared to each drug when administered independently.
The next step was using chemical modifications to enable bonding between the polymeric carrier and the chosen drugs. This combined system can travel through the body with total safety, inflicting no damage to healthy tissues. Upon reaching the cancer cells, the nanocarrier encounters proteins of the cathepsins enzyme family, which are highly activated in malignant tumors. The proteins degrade the polymer, releasing the drugs which become active and join forces to attack the tumor. “It’s like several passengers riding in one cab and getting off together at the same address,” Prof. Satchi-Fainaro explains. “They all arrive at the same destination, right at the same time.”
Tested on a mouse model of melanoma, the new treatment showed promising results. The nanocarrier delivered the two drugs to the tumor and released them there simultaneously in quantities about 20 times greater than those that reach the tumor when similar doses of the same medications are administered independently. In addition, the therapeutic effect achieved by the drugs delivered by the nanocarrier lasted twice to three times longer compared to a control group and a group treated with free medications.
According to the researchers, this means that the new platform enables much lower dosages — about one-third of the dose required in regular drug cocktails. The treatment as a whole is also both safer and more effective. If necessary, the new approach allows for dosages that are much higher than the maximum dosage permissible in current methods, thereby enhancing the effectiveness of the treatment even further.
“In this project, we developed an innovative drug delivery system for treating melanoma, delivering two proven medications and releasing them simultaneously at the tumor site,” Prof. Satchi-Fainaro summarizes. “The treatment proved both safer and more effective than the same medications administered as a cocktail. Moreover, our new platform is highly modular and can be used for delivering a vast range of medications. We believe that its potential for enhancing therapeutics for different diseases is practically endless.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Melanoma
- Knocking out alpha-synuclein in melanoma cells dysregulates cellular iron metabolism and suppresses tumor growthon March 4, 2021 at 9:07 am
The protein alpha-synuclein (α-syn) is unusual because, depending on its conformation and the type of cell in which it is expressed, it is pro-death or pro-survival, triggering neurodegeneration in ...
- Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doublingon March 4, 2021 at 4:30 am
The genetic changes that occur in late stage metastatic melanoma are not well delineated. Here, the authors use rapid autopsy samples from metastatic melanoma patients and show that the late stage in ...
- Dermatologist says Hawke's Bay melanoma rates 'frightening'on March 3, 2021 at 1:20 pm
A dermatologist who moved from the United Kingdom to Hawke's Bay a year ago has been stunned by the amount of skin cancer in the region. In 2018, New Zealand had the second-highest incidence age ...
- A simple blood draw may help discover tumor reactive immune cells to treat advanced melanomaon March 2, 2021 at 5:07 pm
According to a new study led by Yale Cancer Center and Department of Neurology researchers, a simple blood draw may be the first step in helping to discover tumor reactive immune or T cells to treat ...
- Highlight & Pivotal start Phase IIa melanoma trialon March 2, 2021 at 4:08 am
Highlight Therapeutics and Pivotal work together on Melanoma therapy andlaunch a Phase IIa trial to examine BO-112 efficacy and safety Trial will examine administration of Highlight's BO-112 in ...
Go deeper with Google Headlines on:
Melanoma
Go deeper with Bing News on:
Nanotechnological drug delivery
- Evonik partners with BioNTech to manufacture lipids for COVID-19 vaccineon March 2, 2021 at 3:02 pm
In terms of vaccine development, as one of the worst public health crises in living memory, the COVID-19 pandemic has stimulated an enormous feat of nanotechnological ... leader for advanced drug ...
- The superspreaders behind top COVID-19 conspiracy theorieson February 15, 2021 at 9:12 am
He maintains it shows signs of nanotechnological tinkering and the insertion of proteins from HIV, the human immunodeficiency virus. He alleges that U.S. researchers helped create it, and that ...
- The superspreaders behind top COVID-19 conspiracy theorieson February 14, 2021 at 9:16 pm
He maintains it shows signs of nanotechnological tinkering and the insertion of proteins from HIV, the human immunodeficiency virus. He alleges that U.S. researchers helped create it, and that ...
- Nanotechnological Strategies for Therapeutic Targeting of Tumor Vasculatureon February 11, 2021 at 4:00 pm
Cancer nanotechnology, as an integrated platform, offers great opportunities for optimizing drug efficacy and pharmacokinetics ... be utilized for selective delivery of chemotherapeutics to ...
- Nanotechnological Strategies for Therapeutic Targeting of Tumor Vasculatureon February 8, 2021 at 4:00 pm
It becomes evident that tumor vasculature is a highly accessible and convenient target for drug delivery. However, most therapeutic agents, especially chemotherapy, have no intrinsic affinity for ...